Category: News

Zurich / Singapore, June 2016 – Venture Valuation together with KPMG and its new partner EuropaBio has released its third Report on “Site Selection for Life Sciences companies in Europe”. The report now also added additional countries including Denmark, Finland, Italy, Spain and Sweden. The report looks at the strength of Biotechnology, Medical Technology and Pharma.

In response to this growing need of life sciences companies for comprehensive and unbiased information on various countries and their ability to host key value drivers, KPMG, in collaboration with Venture Valuation and EuropaBio has published its report “Site Selection for Life Sciences Companies in Europe” for the third time.

As in past years, the report offers a comprehensive and unique overview of the various aspects relevant for smart site selection, such as size and specialization of the clusters, business-friendly legislation, macroeconomics and, naturally, the tax system. This combination of operational aspects and tax considerations gives life science companies a first insight into how their new or redesigned value chain could look from a location point of view.

Life Sciences clusters in Europe
According to the report, there are basically three types of European countries attractive to locate key value drivers of life science companies

1. Countries with strong clusters of life science companies and an attractive tax and business environment.
2. Countries that have significant clusters of life science companies in their jurisdictions, but lack the benefits of an attractive business environment.
3. Countries which have attractive business and tax regimes without the support of a strong domestic biopharmaceutical industry.

 
All three types of countries can offer appealing opportunities for hosting certain key value drivers of life science companies.

“We are happy to have extended the report to include additional countries and also to have found a new partner in EuropaBio to help promote the European Biotechnology and Life Sciences industry. The Report also provides a comparison of the key European clusters with the BayArea to give an international benchmark. Using Biotechgate as a basis for the data collection is a big advantage, as it tracks over 40,000 companies and its assets / licensing opportunities worldwide.”
Dr. Patrik Frei, CEO of Venture Valuation / Biotechgate, Singapore/Switzerland
 
To download the report please click here »
 
About us:

Biotechgate (www.biotechgate.com)
The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 40,000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals, associated financial information on individual deals and a unique life sciences investors database.
 
Venture Valuation AG (www.venturevaluation.com)
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland/Ireland/UK (Europe), USA/Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.

 For further information, please contact: Patrik Frei, CEO Venture Valuation, contact@venturevaluation.com

Biotechgate, owned by Venture Valuation has partnered with Nasdaq GlobeNewswire to distribute Nasdaq’s GlobeNewswire press releases on Biotechgate and all its related country portals.

Through the collaboration, Biotechgate will provide Nasdaq GlobeNewswire with an additional worldwide and focused publication channel. Biotechgate will publish the Biotech and life science related news on its website www.biotechgate.com and make it available free of charge to all its users. In addition the GlobeNewswire press releases are made available step-by-step on the 30 country specific life sciences directories run by Biotechgate, such as the Swiss Life Sciences Database (www.swisslifesciences.com) or the UK Biotech Database (www.ukbiotech.com). Where possible, press releases are linked to the specific company profiles which are available in the global Biotechgate database.

Jost Renggli, COO of Venture Valuation / Biotechgate said: “This feed of news and press releases from GlobeNewswire adds great value to our global company directory. Users are able, not just to find new partners on our website, but also the latest news about the specific company.”

The Biotechgate Database is property of Venture Valuation AG, headquartered in Switzerland with offices in Singapore, UK, Ireland and the US. Biotechgate is a directory with more than 38,000 company profiles, pipeline products and management details. Life sciences executives around the globe use Biotechgate to identify new business partners or licensing opportunities. All data in the database is updated on an ongoing basis.

Zurich / Melbourne, November 2015: Venture Valuations Biotechgate and AusBiotech, the Australian Biotech Industry Association, have entered into an agreement to create a comprehensive directory of Australian biotechnology and life science companies and extend the network and reach of Biotechgate.

The Australian Life Sciences Directory will have a standalone web address and will also be a part of the larger Biotechgate global life science database (www.biotechgate.com), which includes more than 35,000 company profiles. Thanks to a comprehensive search form and automated alerts, it allows users to seek for specific companies filtering by sectors, indications, product phase and many other categories. Biotechgate produces directories for the largest life sciences clusters in the world, including BioCom in San Diego, Canada, France, Germany, Maryland, Sweden, Switzerland and UK.

Dr Anna Lavelle, CEO of Ausbiotech said: “We are pleased to be able to deliver this initiative in support of Australian biotech companies. Support tools like this new Australian directory help sector growth by enabling communication, linkages and access.”

Dr Patrik Frei, CEO of Venture Valuation said: “Increasing our Australian exposure has been important in the last 18 months and we are very happy to have one of the world’s most important biotech clusters as a partner. The database will help to provide foreign companies better access to innovative companies in Australia.”

The Biotechgate Database is the property of Venture Valuation AG, Switzerland. Biotechgate is a global life science database providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.

The Australian Life Sciences Directory will be initially set up with publicly available information via company websites and once launched and live, companies will be able to log in and update and tailor their details.

Patrik Frei, CEO Venture Valuation (on the left) is signing the contract with Glenn Cross, COO AusBiotech.
 

About us:

Biotechgate (www.biotechgate.com)
The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 35,000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.

Venture Valuation AG (www.venturevaluation.com)
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland (Europe), Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.

For further information, please contact: Patrik Frei, CEO Venture Valuation, contact@venturevaluation.com | +41 43 321 8660

Zurich / Singapore, November 2015 – Venture Valuation together with KPMG has released its 2015 Report on “Site Selection for Life Sciences companies in Europe”. The report looks across the European Life Sciences landscape, analysing and comparing 14 European countries. The report looks at the strength of Biotechnology, Medical Technology and Pharma.

This second edition report provides an in depth analysis of seven key life sciences clusters across Europe including Belgium, France, Germany, Ireland, Netherlands, Switzerland and the United Kingdom. These countries were chosen as they represent the main locations to attract direct foreign investment according to KPMG.

The data in the report is based on Venture Valuation’s global Biotechgate database with over 37,000 companies. In total 14 European countries including Austria, Denmark, Finland, Italy, Norway, Spain, Sweden (plus the 7 previously listed countries) are analysed along with Israel and the BayArea in the US. Venture Valuation analysed the number of Life Sciences companies in Biotechnology, Biotechnology – Therapeutics, Medical Technology and Pharma and reviewed their main activities with regards to R&D and manufacturing. A focus is also put on the numbers and activities of global and regional headquarters. The report provides information on the strength of the development pipeline, the therapeutic focus of each country and for each stage of development. Venture valuation also provides a detailed financial analysis on how much money has been raised by companies in the different countries, from the different sectors, looking at private and publicly listed companies.

Germany has the highest number of Biotechnology companies, however, the UK has the higher number of Biotechnology companies developing therapeutics, an indication for innovation. Regarding the pipeline, it is again the UK who leads, followed by Germany, France and Switzerland. In 2015 (Jan-Jul) UK and Swiss private companies raised around 75% of the total money raised by private European companies. Looking at public companies, Dutch and Irish companies raised the most alongside UK companies.

“This new report provides an excellent overview of the European Life Sciences Industry, especially focusing on private, unlisted companies. As this data is difficult to find, the small companies are often not included in such reports. With our unique global database, we can provide very detailed statistical information. Within Biotechgate, we have every single company / asset and financing round listed in our publicly available database, which provides transparency.”
Dr. Patrik Frei, CEO of Venture Valuation / Biotechgate, Singapore/Switzerland

To download the report please click here »

About us:

Biotechgate (www.biotechgate.com)
The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 37,000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.

Venture Valuation AG (www.venturevaluation.com)
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland (Europe), Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.

For further information, please contact: Patrik Frei, CEO Venture Valuation, Singapore
contact@venturevaluation.com | +41 43 321 8660

Singapore / Taipei, June 2015 – Venture Valuation owned Biotechgate announces the partnership with Taiwan Bio Industry Organization to create a directory of Taiwanese Biotech companies. The database is the launch of a collaborative promotion of BIO Taiwan, one of the key Biotech and Life Sciences events in Asia. 

The Taiwanese Biotech Directory (www.taiwanesebiotech.com and www.taiwaneselifesciences.com) are part of Biotechgate a global life science database, (www.biotechgate.com) which includes more than 35’000 company profiles. Thanks to a comprehensive search form and automated alerts, it allows users to seek for specific companies filtering by sectors, indications, product phase and many other categories.  Taiwan Bio Industry Organization is the Biotech Organisation of Taiwan with over 400 members. Taiwan Bio is also the organizer of the yearly Bio Taiwan (July 22 to July 26, 2015 in Taipei). The database for Taiwan is launched to promote the companies of Taiwan, to provide them a window to the world and allow foreign companies to see the diversity in Taiwan Biotech Industry. Bio Taiwan is an ideal place for overseas companies to meet with innovative companies.

“Taiwan is a key cluster in Asia and we are happy to be part of the global Biotechgate database. Our BioTaiwan annual event is an important gathering of key opinion leaders, innovative companies in the region and had become popular also with overseas organisations.“ Dr. Johnsee Lee, Honorary Chairman of Taiwan BIO and the Chairman of BioTaiwan 2015 Organizing Committee.

“Increasing our Asian exposure has been key in the last 18 month and we are very happy to have one of the key Biotech clusters in the region as a partner. We are looking forward to participate in the BioTaiwan event this year in July. The database will help to provide foreign companies better access to innovation in Taiwan.” Dr. Patrik Frei, CEO of Venture Valuation / Biotechgate, Singapore/Switzerland

About us:
Biotechgate (www.biotechgate.com)
The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Science Database containing over 35’000 company profiles and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals.

Venture Valuation AG (www.venturevaluation.com)
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging life sciences companies (biotechnology, med-tech and pharma). Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland (Europe), Canada (North America) and Singapore (APAC), Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.

Taiwan Bio Industry Organization (http://taiwanbio.org.tw/eng)
Taiwan Bio Industry Organization (TBIO) was established in 1989, is the largest and the most influential biotechnology organization in Taiwan. TBIO represents over 400 members ranging from private companies and academic institutes to government bodies involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology. Our mission is to provide advocacy, business development and communication service for our members. TBIO organize the annual BioTaiwan event, one of the largest gatherings of biotechnology industry in Asia. BioTaiwan 2015 will be held July 22-26 in Taipei (www.bio-taiwan.com) with series of BioBusiness Asia Conference, Conference on Greater China Opportunities, Company Presentation and One-on-one Partnering, seminars and workshops and exhibition with over 600 companies.

For further information, please contact: Patrik Frei, CEO Venture Valuation, Singapore+65 (31) 590 721, support@biotechgate.com

Click here to download the press release : Biotechgate/Venture Valuation partners with Taiwan BIO, Switzerland /Taiwan, June 2015, 1 page, 200kb

Switzerland / Finland, February 2015 – As a result of the partnership with Turku Science Park Ltd, Biotechgate gained its first partner in Finland. This partnership closes an important gap in the Nordic Life Science Database. 

Turku Science Park (Finland) is now an official partner of Biotechgate and the Nordic Life Science Database. Thanks to this partnership, profiles of more than 200 life science companies from the region of Turku can be explored for free on www.nordic-lifesciences.com as well as on the website of Turku Science Park (www.turkusciencepark.com/fi/company-database). This directory is maintained and further completed on an ongoing basis.

The Finnish companies are also part of the global life science directory Biotechgate which contains profiles of more than 35,000 players from the Medtech, Biotech and Pharma field. Biotechgate also contains more detailed information on the Finnish company profiles, such as management contacts, financing rounds and product pipelines. Life Science executives use Biotechgate to identify emerging Biotech and Medtech companies, licensing opportunities, collaboration partners, etc. worldwide.Thanks to additional partners from Sweden, and Denmark, company profiles from these countries can be found and viewed for free on the Nordic Life Sciences Database. As a result of various search features the information is easily accessible.

“Joining Biotechgate was the result of a thorough analysis process to bring more business opportunities and visibility to Turku based life science companies and to BioTurku. We hope this will increase business and generate science co-operation between our region and companies globally.”
Tero Karhi, Project Manager, Turku Science Park Oy Ltd

“Having Turku Science Park on board as a partner, means we can close an important gap in the Nordic Life Science Database and in Biotechgate. After our great experience with our existing partners in Norway, Sweden and Denmark, we are looking forward to seeing the Nordic region growing in our database. We are convinced this is a great contribution to life science executives inside and outside of Finland.”
Jost Renggli, COO, Venture Valuation / Biotechgate

For further information, please contact:

Jost Renggli, COO Biotechgate / Venture Valuation, Switzerland

+41 (43) 321 86 60, support@biotechgate.com

Click here to download the press release : Biotechgate expands to Finland: We welcome our new partner Turku Science Park, Switzerland /Finland, March 2015, 2 pages, 172kb